RCM
DYN icon

Ratan Capital Management’s Dyne Therapeutics DYN Stock Holding History

Ratan Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-98,900
Closed -$1.03M – 33
2025
Q1 		$1.03M Sell
98,900
-132,000
-57% -$1.89M 0.33% 25
2024
Q4 		$5.44M Hold
230,900
– – 0.83% 25
2024
Q3 		$8.29M Hold
230,900
– – 2.24% 14
2024
Q2 		$8.15M Buy
230,900
+201,900
+696% +$5.87M 2.47% 11
2024
Q1 		$823K Buy
+29,000
New +$656K 0.44% 31

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ratan Capital Management's DYN Position: Q2 2025 in Review

Ratan Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 98,900 shares — an estimated $1.03M sold.

Ratan Capital Management first reported a position in DYN in Q1 2024 and held it in 5 quarters. The position peaked at $8.29M in Q3 2024. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Ratan Capital Management reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ratan Capital Management sold 98,900 Dyne Therapeutics shares in Q2 2025, an estimated $1.03M.
  • Ratan Capital Management first reported a position in Dyne Therapeutics in Q1 2024 and held it in 5 quarters.
  • Ratan Capital Management's Dyne Therapeutics position peaked at $8.29M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Ratan Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.